Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

14 Nov 2024 CMB International Global Markets | Equity Research | Company Update BeiGene (BGNE US) Growing non-GAAP profit ■ Strong product sales. In 3Q24, BeiGene recorded product sales of US$993mn (+8% QoQ, +67% YoY). The 9M24 total product sales reached US$2.66bn, representing 69% of our previous FY24 estimate. In 3Q24, sales of zanubrutinib (Zanu) increased 8% QoQ or 93% Yo Y to US$690mn. The growth rate in Q3 was notably slower compared to the 30% QoQ increase in Q2, primarily due to a one- off sales or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ___________________________________________________________ FORM 10-Q ___________________________________________________________ For the transition period from to Commission File Number: 001-376 ...

Exhibit 99.1 BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates • Continued financial progress with $1 billion in quarterly total revenue, reduced GAAP loss and second consecutive quarter of positive non-GAAP operating income • Strengthened franchise leadership in chronic lymphocytic leukemia (CLL) with foundational therapy BRUKINSA, global revenue of $690 million, rapidly progressing pivotal programs for late-stage hematology pipeline • Expanded oncology pipeline with four new mol ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

BeiGene, Ltd. (BGNE) shares soared 5.3% in the last trading session to close at $246.04. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 22% gain over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the performance of the company’s marketed portfolio of drugs. Beigene currently has three approved medicines – Brukinsa (various blood cancers), Tevimbra (various sol ...

Exhibit 99.1 BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates • Generated total revenues of $929 million, an increase of 56% from the prior-year period; reduced GAAP operating loss and achieved non-GAAP operating income • Strengthened hematology leadership with global BRUKINSA revenues of $637 million, an increase of 107% from the prioryear period; advanced pivotal programs for BCL2 inhibitor sonrotoclax and BTK-targeted degrader BGB ...

Shares of BeiGene, Ltd. (BGNE) have gained 28.8% over the past four weeks to close the last trading session at $202.17, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $258.45 indicates a potential upside of 27.8%.The mean estimate comprises 11 short-term price targets with a standard deviation of $55.54. While the lowest estimate of $152 indicates a 24.8% decline from the curre ...

BeiGene, Ltd. (BGNE) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, BGNE's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typic ...

Shares of BeiGene, Ltd. (BGNE) have gained 20.1% over the past four weeks to close the last trading session at $182.76, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $257.41 indicates a potential upside of 40.9%.The mean estimate comprises 11 short-term price targets with a standard deviation of $56.75. While the lowest estimate of $161 indicates a 11.9% decline from the curre ...